NewAmsterdam Pharma (NAMS) Revenue (2023 - 2026)

NewAmsterdam Pharma has disclosed Revenue across 4 years of filings, most recently posting $3.0 million for Q1 2026.

• Revenue for Q1 2026 came in at $3.0 million, up 2.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.6 million (down 52.13% YoY), and the FY2025 annual result was $22.5 million, down 50.61% from the prior year.
• Revenue came in at $3.0 million for Q1 2026 at NewAmsterdam Pharma, up from $32000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $29.1 million in Q3 2024 to a low of $32000.0 in Q4 2025.
• The 4-year median for Revenue is $2.9 million (2023), against an average of $6.6 million.
• Across the five-year window, Revenue surged 1490.54% in 2024 and sank 99.75% in 2025, its largest moves.
• NewAmsterdam Pharma's Revenue stood at $803000.0 in 2023, then soared by 1490.54% to $12.8 million in 2024, then tumbled by 99.75% to $32000.0 in 2025, then soared by 9400.0% to $3.0 million in 2026.
• The last three Revenue figures came in at $3.0 million (Q1 2026), $32000.0 (Q4 2025), and $348000.0 (Q3 2025), per Business Quant data.